Original language | English |
---|---|
Pages (from-to) | e228-e229 |
Journal | The Lancet Oncology |
Volume | 22 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Jun 2021 |
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: The Lancet Oncology, Vol. 22, No. 6, 01.06.2021, p. e228-e229.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Unresolved questions regarding the promise of the TPEx regimen – Authors' reply
AU - Guigay, Joël
AU - Auperin, Anne
AU - Fraslin, Aldéric
AU - Keilholz, Ulrich
AU - Bourhis, Jean
AU - Mesia, Ricard
N1 - Funding Information: JG has received research grants from Boehringer Ingelheim, Bristol Myers Squibb (BMS), Chugai, GlaxoSmithKline, Merck Serono, and Sanofi; and has been an advisory board member for AstraZeneca, BMS, Innate Pharma, and Merck, all outside the submitted work. AA has received grant support, paid to her institution, from the Groupe d'Oncologie Radiotherapie Tête et Cou (GORTEC; French Radiation and Oncology Group for Head and Neck) for the original study and has received grant support, paid to her institution, from F Hoffmann–La Roche, outside the submitted work. AF has received grant support, paid to his institution, from the GORTEC for the original study. UK has received grants and personal fees from Merck, outside the submitted work. JB participated in advisory boards for Merck Sharp & Dohme, BMS, Debiopharm, Merck, and AstraZeneca, outside the submitted work. RM has received research grants from Merck Serono and has been an advisory board member for AstraZeneca, BMS, Rakuten, Merck Serono, Merck Sharp & Dohme, Nanobiotics, Bayer, and Roche, all outside the submitted work.
PY - 2021/6/1
Y1 - 2021/6/1
UR - http://www.scopus.com/inward/record.url?scp=85107132945&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(21)00293-X
DO - 10.1016/S1470-2045(21)00293-X
M3 - Letter
C2 - 34087138
AN - SCOPUS:85107132945
SN - 1470-2045
VL - 22
SP - e228-e229
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 6
ER -